WO2000064486A3 - Enzymatically activated polymeric drug conjugates - Google Patents

Enzymatically activated polymeric drug conjugates

Info

Publication number
WO2000064486A3
WO2000064486A3 PCT/US2000/011670 US0011670W WO0064486A3 WO 2000064486 A3 WO2000064486 A3 WO 2000064486A3 US 0011670 W US0011670 W US 0011670W WO 0064486 A3 WO0064486 A3 WO 0064486A3
Authority
WO
WIPO (PCT)
Prior art keywords
conjugates
polymeric drug
drug conjugates
water soluble
chemical moiety
Prior art date
Application number
PCT/US2000/011670
Other languages
French (fr)
Other versions
WO2000064486A2 (en
Inventor
James M Pachence
Benjamin A Belinka
Thulasi Ramani
Original Assignee
Veritas Medical Technologies I
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veritas Medical Technologies I filed Critical Veritas Medical Technologies I
Priority to EP00928630A priority Critical patent/EP1176985A2/en
Priority to CA002369999A priority patent/CA2369999A1/en
Priority to JP2000613476A priority patent/JP2002542304A/en
Priority to AU46835/00A priority patent/AU772074B2/en
Publication of WO2000064486A2 publication Critical patent/WO2000064486A2/en
Publication of WO2000064486A3 publication Critical patent/WO2000064486A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

The present invention relates to a polymeric drug conjugate with one or more biologically active agents conjugated via an enzymatically cleavable linker to either a regular repeating linear unit comprising a water soluble polymer segment and a multifunctional chemical moiety, or a branched polymer comprising two or more water soluble polymer segments each bound to a common multifunctional chemical moiety, as well as to methods of making such conjugates. The present invention is also directed to pharmaceutical compositions comprising such conjugates and to the use of such conjugates to treat pathological conditions.
PCT/US2000/011670 1999-04-28 2000-04-28 Enzymatically activated polymeric drug conjugates WO2000064486A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP00928630A EP1176985A2 (en) 1999-04-28 2000-04-28 Enzymatically activated polymeric drug conjugates
CA002369999A CA2369999A1 (en) 1999-04-28 2000-04-28 Enzymatically activated polymeric drug conjugates
JP2000613476A JP2002542304A (en) 1999-04-28 2000-04-28 Enzymatically activated polymerized drug conjugate
AU46835/00A AU772074B2 (en) 1999-04-28 2000-04-28 Enzymatically activated polymeric drug conjugates

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13140499P 1999-04-28 1999-04-28
US60/131,404 1999-04-28
US16309099P 1999-11-02 1999-11-02
US60/163,090 1999-11-02

Publications (2)

Publication Number Publication Date
WO2000064486A2 WO2000064486A2 (en) 2000-11-02
WO2000064486A3 true WO2000064486A3 (en) 2001-04-26

Family

ID=26829434

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/011670 WO2000064486A2 (en) 1999-04-28 2000-04-28 Enzymatically activated polymeric drug conjugates

Country Status (5)

Country Link
EP (1) EP1176985A2 (en)
JP (1) JP2002542304A (en)
AU (1) AU772074B2 (en)
CA (1) CA2369999A1 (en)
WO (1) WO2000064486A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9504755B2 (en) 2008-08-11 2016-11-29 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01011502A (en) * 1999-05-14 2003-08-20 Boehringer Ingelheim Pharma Enzyme-activated anti-tumor prodrug compounds.
US6613879B1 (en) 1999-05-14 2003-09-02 Boehringer Ingelheim Pharma Kg FAP-activated anti-tumour compounds
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
US6380405B1 (en) 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
US6541508B2 (en) 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs
DE10018617A1 (en) * 2000-01-13 2001-10-31 Joerg G Moser Cyclodextrin dimers with peptide spacer structures for detoxification of active pharmaceutical ingredients with high potential for side effects
EE200200522A (en) 2000-03-15 2004-04-15 Bristol-Myers Squibb Pharma Company The enzyme-cleaving peptide conjugated to the active ingredient, a pharmaceutical composition containing it and its use as an antitumor drug
EP1274460A4 (en) * 2000-04-15 2005-06-29 Kolon Inc Aqueous-prodrug compound comprising moiety of paclitxel or derivatives thereof, method of preparing same and pharmaceutical composition comprising same
US7105482B2 (en) 2000-11-01 2006-09-12 Praecis Pharmaceuticals, Inc. Methionine aminopeptidase-2 inhibitors and methods of use thereof
US6548477B1 (en) 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
EP1330447A2 (en) * 2000-11-01 2003-07-30 Praecis Pharmaceuticals Incorporated Peptides as met-ap2 inhibitors
US6919307B2 (en) 2000-11-01 2005-07-19 Praecis Pharmaceuticals, Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
JP4290352B2 (en) * 2001-05-17 2009-07-01 独立行政法人科学技術振興機構 Cell signal responsive gene transcription control system
JP4840837B2 (en) * 2001-09-28 2011-12-21 日本たばこ産業株式会社 Novel peptide having umami taste and seasoning containing umami ingredient
GR20020100189A (en) * 2002-04-17 2003-12-22 Zeincro Ελλας Ανωνυμη Εταιρεια Συμβουλων Φαρμακευτικων Επιχειρησεων Prostate specific membane antigen prodrugs
ATE403448T1 (en) * 2003-04-28 2008-08-15 Johnson & Johnson Medical Ltd PAIN-SENSITIVE THERAPEUTIC WOUND DRESSINGS
GB2402677A (en) * 2003-05-06 2004-12-15 Sirus Pharmaceuticals Ltd Biodegradable polymer
US7947261B2 (en) * 2003-05-23 2011-05-24 Nektar Therapeutics Conjugates formed from polymer derivatives having particular atom arrangements
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
KR20120073370A (en) * 2003-09-17 2012-07-04 넥타르 테라퓨틱스 Multi-arm polymer prodrugs
CA2559188C (en) 2004-03-05 2013-01-08 Denki Kagaku Kogyo Kabushiki Kaisha Hyaluronic acid-methotrexate conjugate
WO2005095441A1 (en) * 2004-03-31 2005-10-13 National Institute Of Advanced Industrial Science And Technology Epithelial cell growth promoter
US7807675B2 (en) * 2004-04-02 2010-10-05 Denki Kagaku Kogyo Kabushiki Kaisha Hyaluronic acid-methotrexate conjugate
EP2348114B1 (en) 2004-04-21 2018-07-25 Alexion Pharmaceuticals, Inc. Bone delivery conjugates and method of using same to target proteins to bone
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
US8067376B2 (en) * 2004-11-03 2011-11-29 Forhumantech Co., Ltd. Pharmaceutical compositions for transdermal delivery
DE102005007468A1 (en) * 2005-02-16 2006-08-31 Beiersdorf Ag Covalently bound active complexes, from which stress-activatable skin enzymes release an active substance
US7462627B2 (en) 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
US7671067B2 (en) 2006-02-09 2010-03-02 Enzon Pharmaceuticals, Inc. Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
JP2010501026A (en) * 2006-06-30 2010-01-14 インターフェース バイオロジクス，インコーポレーテッド Bioresponsive polymer
JP5277417B2 (en) 2006-11-30 2013-08-28 ネクター セラピューティクス Method for preparing a polymer composite
RU2009133793A (en) 2007-02-09 2011-03-20 Энзон Фармасьютикалз, Инк. (Us) TREATMENT OF RESISTANT OR UNRELIABLE CANCER FORMS WITH 7-ETHYL-10-HYDROXYCAMPOTECINE CONJUGATES WITH MULTIPLE CHAIN BRANCHES
WO2009140683A1 (en) * 2008-05-16 2009-11-19 Research Foundation Of The City University Of New York Living copolymer protein/peptide hybrids for biomedical applications
ES2744975T3 (en) 2008-09-23 2020-02-27 Nektar Therapeutics Metronome dosage method with camptothecin prodrugs (eg PEG-Irinotecan)
KR20130118203A (en) 2010-04-30 2013-10-29 알렉시온 파마 인터내셔널 에스에이알엘 Methods, compositions, and kits for the treatment of matrix mineralization disorders
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
CA2823066A1 (en) 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
JP5926374B2 (en) 2011-06-10 2016-05-25 メルサナ セラピューティクス，インコーポレイティド Protein-polymer-drug conjugate
JP6336902B2 (en) 2011-06-22 2018-06-06 ビョーメ バイオサイエンシズ ピーブイティー．リミテッド Conjugate-based antifungal and antibacterial prodrugs
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
NL2010040C2 (en) * 2012-12-21 2014-06-24 Internat Inst For Diagnostic And Analitical Affairs B V Cleavable coating material having microbial functionality.
CN105813655B (en) 2013-10-11 2022-03-15 阿萨纳生物科技有限责任公司 Protein-polymer-drug conjugates
ES2726850T3 (en) 2013-10-11 2019-10-09 Mersana Therapeutics Inc Protein-polymer-drug conjugates
WO2015179402A1 (en) 2014-05-19 2015-11-26 North Carolina State University Methods of folding a graft copolymer with dual anticancer drugs and related applications
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
JP6516235B2 (en) * 2014-10-31 2019-05-22 国立大学法人富山大学 Chimeric protein and microglial activity inhibitor using the same
EP3226891A1 (en) 2014-12-05 2017-10-11 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
US10603361B2 (en) 2015-01-28 2020-03-31 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
US11352612B2 (en) 2015-08-17 2022-06-07 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
JP6868617B2 (en) 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド Identifying effective dosing regimens for tissue-nonspecific alkaline phosphatase (TNSALP) enzyme replacement therapy for hypophosphataseemia
JP2018533571A (en) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド Methods for treating cranial suture early healing disease in a patient
EP3426286A4 (en) 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
US11186832B2 (en) 2016-04-01 2021-11-30 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
US11116821B2 (en) 2016-08-18 2021-09-14 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
EP3554548A4 (en) 2016-12-19 2020-08-19 The Regents of The University of California Noncrushable pill formulatiions
WO2018118902A1 (en) 2016-12-19 2018-06-28 The Regents Of The University Of California Dual-enzyme responsive peptides
EP3600383A4 (en) 2017-03-31 2020-10-28 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (hpp) in adults and adolescents
KR102095284B1 (en) * 2017-05-11 2020-04-01 (주)케어젠 Conjugate of methotrexate and peptide
WO2019190752A1 (en) 2018-03-30 2019-10-03 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016555A1 (en) * 1991-03-18 1992-10-01 Enzon, Inc. Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
EP0712635A1 (en) * 1994-05-13 1996-05-22 Kuraray Co., Ltd. Medical polymer gel
EP0838224A2 (en) * 1996-10-02 1998-04-29 Kuraray Co., Ltd. Polymer-drug conjugates with an enzyme cleavable linker
WO1998019705A1 (en) * 1996-11-05 1998-05-14 Bristol-Myers Squibb Company Branched peptide linkers
WO2000040203A2 (en) * 1999-01-08 2000-07-13 Emisphere Technologies, Inc. Polymeric delivery agents and delivery agent compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016555A1 (en) * 1991-03-18 1992-10-01 Enzon, Inc. Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
EP0712635A1 (en) * 1994-05-13 1996-05-22 Kuraray Co., Ltd. Medical polymer gel
EP0838224A2 (en) * 1996-10-02 1998-04-29 Kuraray Co., Ltd. Polymer-drug conjugates with an enzyme cleavable linker
WO1998019705A1 (en) * 1996-11-05 1998-05-14 Bristol-Myers Squibb Company Branched peptide linkers
WO2000040203A2 (en) * 1999-01-08 2000-07-13 Emisphere Technologies, Inc. Polymeric delivery agents and delivery agent compounds

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRINKLEY M: "A BRIEF SURVEY OF METHODS FOR PREPARING PROTEIN CONJUGATES WITH DYES, HAPTENS, AND CROSS-LINKING REAGENTS", BIOCONJUGATE CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY, WASHINGTON, vol. 3, no. 1, 1992, pages 2 - 13, XP000261480, ISSN: 1043-1802 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; CALICETI P ET AL: "Preparation and properties of monomethoxy poly(ethylene glycol) doxorubicin conjugates linked by an amino acid or a peptide as spacer.", XP002156126, retrieved from STN Database accession no. 94000214 *
FARMACO, (1993 JUL) 48 (7) 919-32. *
NICHIFOR M. ET AL: "Polymeric prodrugs of 5-fluorouracil.", JOURNAL OF CONTROLLED RELEASE, (1997) 48/2-3 (165-178)., XP004125853 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9504755B2 (en) 2008-08-11 2016-11-29 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates

Also Published As

Publication number Publication date
EP1176985A2 (en) 2002-02-06
AU772074B2 (en) 2004-04-08
AU4683500A (en) 2000-11-10
CA2369999A1 (en) 2000-11-02
JP2002542304A (en) 2002-12-10
WO2000064486A2 (en) 2000-11-02

Similar Documents

Publication Publication Date Title
WO2000064486A3 (en) Enzymatically activated polymeric drug conjugates
WO2004110358A3 (en) Polymeric conjugates for tissue activated drug delivery
ATE356638T1 (en) HYDROLYTICALLY DEGRADABLE CARBAMAT DERIVATIVES OF POLYETHYLENE GLYCOL
WO2003040211A3 (en) Branched polymers and their conjugates
AU2001288829A1 (en) Degradable polyacetal polymers
WO2003061577A8 (en) Polyalkylene glycol with moiety for conjugating biologically active compound
WO2004075923A3 (en) Polymer-factor viii moiety conjugates
WO2001062300A3 (en) Caspase activated prodrugs therapy
WO2008076333A3 (en) Polymer-drug conjugates with tether groups for controlled drug delivery
DE69925830D1 (en) PEG-LHRH ANALOG CONJUGATE
EP1292709A4 (en) Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
DE60004172D1 (en) GCSF CONJUGATE
HUP0203123A2 (en) Process for preparation of polyglutamate-therapeutic agent conjugates
CA2331264A1 (en) Compositions and methods for drug delivery
HK1092708A1 (en) Polyacetal drug conjugates as release system
DE69830326D1 (en) IMINING POLYSACCHARIDES, THEIR PREPARATION AND USE AS ADDITIVES AND IMMUNOSTIMULATING AGENTS
DE69837443D1 (en) DEGRADABLE POLYETHYLENEGLYCOLHYDROGELE WITH CONTROLLED HALF TIME AND ITS PREPARED PRODUCTS
EP1712228A3 (en) Hyaluronic acid derivatives for the prevention and treatment of cutaneous scars
CA2359318A1 (en) Biomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups
WO2003037384A3 (en) Polymer conjugates of protein kinase c inhibitors
ES2175028T3 (en) PACLITAXEL PROFARMACOS, PREPARATION METHOD AND ITS USE IN SELECTIVE CHEMOTHERAPY.
WO2005053749A3 (en) Thiol-cleavable linkage between polymer and ligand
WO2006005058A3 (en) Polymer-factor ix moiety conjugates
WO2002087497A3 (en) Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use
AU8025998A (en) Biologically active materials

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2369999

Country of ref document: CA

Ref country code: CA

Ref document number: 2369999

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 613476

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 46835/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000928630

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000928630

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 46835/00

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 2000928630

Country of ref document: EP